MacroGenics has expanded its royalty purchase agreement with Sagard Healthcare Partners, receiving a $60 million upfront payment and the potential to earn an additional $20 million based on 2026 sales milestones for ZYNYZ, a cancer treatment drug. The agreement caps Sagard's returns at 1.7x investment by 2032 or 2.0x thereafter, after which royalties revert to MacroGenics. This deal provides MacroGenics with immediate capital while retaining other economic interests in ZYNYZ, which is marketed by Incyte for certain cancers in the US, Europe, and Japan. The expanded agreement supports MacroGenics' ongoing development and commercialization efforts for its antibody-based therapies.
Verra Mobility shares dropped 41.2% in after-hours trading following Avis Budget Group's termination of their contract effective September 2026. This contract loss could reduce Verra's annual Commercial Services revenue by $135-$145 million and segme...
Netcapital Inc. shares surged 19.63% in after-hours trading following the announcement of a business update conference call scheduled for Thursday. The new CEO, Todd Violette, will discuss the company's transformation, priorities, and plans to grow i...
ISS has secured a seven-year contract with West Sussex County Council to deliver around 25,000 nutritious school meals daily to primary schools starting Q3 2026. The contract, valued at about DKK 100 million annually, emphasizes inclusivity and high ...
TGS ASA has secured a large 4D streamer contract offshore Angola, set to begin data acquisition in early July 2026 and last about eight months. This contract strengthens TGS's strategic presence in Africa and ensures vessel utilization into early 202...
Roche has introduced the Liver Disease Panel, the first comprehensive set of certified algorithms designed to improve the detection and management of chronic liver disease (CLD). This panel includes LiverPRO, an algorithm that uses routine blood mark...
